Kenning
Not started
Quick win kit · 7 days · yours forever

How much is too much?
Let’s actually find out.

The internet answers hair loss with a number that was never about you. Five days of counting gives you one that is.

  1. 1
    Name which kind of shedding this isEight questions, about two minutes
  2. 2
    Five days of standardised countingA baseline that is yours, not a population figure
  3. 3
    A verdict, and a page for your doctorSome forms reverse. A small number are time sensitive.
Eight question readFive days of countingChecks for what needs a doctorRepeat the count in eight weeks
ONE

First, which kind of shedding is this?

Six patterns. They do not respond to the same thing.

  • Trigger shedding.Something months ago, showing up now.
  • Pattern thinning.Widening part, thinning crown.
  • Fuel driven shedding.Rapid loss, low intake, hair goes first.
  • Possible thyroid involvement.Hair alongside other changes.
  • Breakage.Snapping mid strand rather than shedding at the root.
  • Scalp driven.Itch, flaking, soreness, tenderness.

Almost every article treats these as one problem. Eight questions, about two minutes, and more than one can be present at once.

FOUR

When hair loss needs a doctor rather than a plan

Most shedding is not dangerous. Follicles that scar do not come back.

Two presentations here are time sensitive for exactly that reason. Read this once now.

Within weeks

Arrange a prompt appointment if you notice

  • One or more new round or oval bald patches
  • Hair loss where the scalp looks unusually smooth or shiny and you cannot see the tiny follicle openings
  • Persistent burning, stinging, tenderness or pain where the hair is thinning
  • Redness or scale clustered around individual hairs, pustules, crusting or drainage
  • Rapid recession of the front or side hairline, especially with eyebrow loss
  • Hair loss that is rapidly worsening, or continuing for more than several months
Same day

Seek urgent medical advice if you notice

  • Rapidly developing coarse facial or body hair together with voice deepening, increasing muscle bulk, or other new changes
  • Sudden major hair loss together with fever, marked weakness, significant weight loss, rash, or feeling acutely unwell
  • A painful, boggy or swollen area of scalp, pus, spreading redness or fever
A smooth or shiny area with loss of visible follicle openings can be a sign of scarring alopecia. In these conditions inflammation can permanently damage follicles, so early diagnosis and treatment matter. This is not usually an emergency department problem, but it should not be watched for months without medical assessment. Arrange a prompt appointment and ask whether dermatology review is appropriate.
Developed by Kenning’s clinical and outcomes research team. Educational only and not medical advice.

If this happens again

You will not be starting over. When it comes back, most often at your next dose increase:

  1. Reopen this kit.
  2. Your previous plan is already saved.
  3. Compare what you are feeling now against your last episode.
  4. Change one thing at a time, so you learn something.
References
  1. Wasko CA, Mackley CL, Sperling LC, Mauger D, Miller JJ. Standardizing the 60-second hair count. Arch Dermatol. 2008;144(6):759-762. PMID 18559765. Describes the counting method used here and reports low variability between consecutive days. Normative values were obtained in men, and the authors state that studies in women remain to be performed, which is why no threshold is applied in this kit.
  2. Miller JJ, Fang S. Results of 60-second timed hair counts in women between the ages of 20 to 60 years. J Am Acad Dermatol. 2004;50(3 suppl):P90.
  3. Malkud S. Telogen effluvium: a review. J Clin Diagn Res. 2015;9(9):WE01-WE03. doi:10.7860/JCDR/2015/15219.6492. PMID 26500992. Reports shedding following the trigger after three to four months, and states that increased telogen shedding does not by itself establish a cause.
  4. Hughes EC, Syed HA, Saleh D. Telogen effluvium. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2024. NBK430848. Describes both the acute and the chronic forms.
  5. Grover C, Khurana A. Telogen effluvium. Cosmetics. 2016;3(2):13. doi:10.3390/cosmetics3020013. Describes chronic telogen effluvium persisting with fluctuation over prolonged periods.
  6. Vujovic A, Del Marmol V. The female pattern hair loss: review of etiopathogenesis and diagnosis. Biomed Res Int. 2014;2014:767628. doi:10.1155/2014/767628. Describes the Ludwig, Olsen and Hamilton patterns and the multifactorial aetiology.
  7. Ramos PM, Anzai A, Duque-Estrada B, et al. Prevalence of female pattern hair loss in postmenopausal women: a cross-sectional study. Menopause. 2022;29(4):415-420. doi:10.1097/GME.0000000000001927. Reports a prevalence of 52.2 percent in postmenopausal women aged 50 to 65.
  8. Management of classic lichen planopilaris: the EADV task force on hair diseases position statement. J Eur Acad Dermatol Venereol. 2026. PMID 41848299. States that inflammation causes permanent damage to follicles and that early diagnosis and prompt intervention are essential. This is the basis for the prompt appointment wording rather than urgent care wording in this kit.
  9. Stege H, Haist M, Schultheis M, et al. Treatment of lichen planopilaris and frontal fibrosing alopecia: a retrospective, real-life analysis in a tertiary center in Germany. J Clin Med. 2024;13(16):4947. doi:10.3390/jcm13164947. Describes irreversible follicular destruction and loss of the stem cell niche.
  10. Branyiczky MK, Towheed T, Beecker J. Effects of GLP-1 receptor agonists on hair loss and regrowth: a systematic review. Int J Dermatol. 2026. doi:10.1111/ijd.70133. Ten studies. Hair loss type was mostly unspecified; where specified, central centrifugal cicatricial alopecia, androgenetic alopecia and telogen effluvium were reported. Pharmacovigilance analyses identified a weak association.
  11. Alopecia as an emerging adverse effect associated with glucagon-like peptide-1 receptor agonists for weight loss: a scoping review. Cureus. 2025. PMC12431796. Nine studies; most lacked dermatological confirmation. Concludes that GLP-1 receptor agonists may alter the hair follicle cycle, and that the evidence remains limited.
  12. Buontempo MG, Alhanshali L, Shapiro J, Lo Sicco K. Exploring the hair loss risk in glucagon-like peptide-1 agonists: emerging concerns and clinical implications. J Eur Acad Dermatol Venereol. 2025. doi:10.1111/jdv.20512. Reports elevated reporting odds ratios for alopecia with semaglutide (2.46) and tirzepatide (1.73), and notes that rapid weight loss may precipitate telogen effluvium.
  13. Kantor J, Kessler LJ, Brooks DG, Cotsarelis G. Decreased serum ferritin is associated with alopecia in women. J Invest Dermatol. 2003;121(5):985-988.
  14. Trost LB, Bergfeld WF, Calogeras E. The diagnosis and treatment of iron deficiency and its potential relationship to hair loss. J Am Acad Dermatol. 2006;54(5):824-844.
  15. Bin Dayel S, Hussein RS, Atia T, et al. Is thyroid dysfunction a common cause of telogen effluvium? A retrospective study. Medicine (Baltimore). 2024;103(1):e36803.

On the mechanism. Hair loss has been reported with these medications, but whether the medication causes it directly, or whether rapid weight loss and nutritional change are responsible, is not established. This kit does not claim to know which applies to you.

On the number. No universal daily shedding figure is used anywhere in this kit. Sources disagree on what normal is, the most commonly quoted range was never intended as a diagnostic threshold, and the available normative counting data was collected in men. Your baseline is compared only with your own.

Developed by Kenning’s clinical and outcomes research team. Educational only and not medical advice. Population specific figures pending clinical sign off.